OA
ITCI icon

Outfitter Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Outfitter Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,450
Closed -$251K – 138
2017
Q1 		$251K Sell
15,450
-3,700
-19% -$53.5K 0.09% 116
2016
Q4 		$289K Buy
+19,150
New +$270K 0.11% 108

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Outfitter Advisors's ITCI Position: Q2 2017 in Review

Outfitter Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2017, closing a stake of 15,450 shares — an estimated $251K sold.

Outfitter Advisors first reported a position in ITCI in Q4 2016 and held it in 2 quarters. The position peaked at $289K in Q4 2016. 100 funds tracked by Wall St. Rank hold ITCI as of Q2 2017.

  • Outfitter Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2017 after selling out during the quarter.
  • Outfitter Advisors sold 15,450 Intra-Cellular Therapies Inc. shares in Q2 2017, an estimated $251K.
  • Outfitter Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 2 quarters.
  • Outfitter Advisors's Intra-Cellular Therapies Inc. position peaked at $289K in Q4 2016.
  • 100 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2017.

Based on Outfitter Advisors's 13F filing for Q2 2017, filed 2 Aug 2017.